The three Houston innovators to know this week represent new, exciting things for the innovation ecosystem. Courtesy photos

The movers and shakers within the Houston innovation ecosystem come from all kinds of industries — from private equity to supercomputing. This week's innovators to know reflect that industry diversity and are bringing something new to the table.

Jon Nordby, managing director of Houston's MassChallenge Texas chapter

Jon Nordby, former exec at Houston Exponential, will lead the inaugural Houston MassChallenge cohort. Courtesy of MassChallenge

Jon Nordby, who recently served as Houston Exponential's director of strategy since its launch, was named as the managing director of MassChallenge Texas in Houston, a zero-equity startup accelerator.

"MassChallenge's not-for-profit, no equity model is uniquely suited to accelerate the development of Houston's innovation ecosystem and is the foundation early-stage startups need to get to the point of disruption or pivot as fast as possible," says Nordby in a release.

Before HX, Nordby served as vice president of talent and innovation at the Greater Houston Partnership, and was essential in creating the organization's Innovation Initiative. Click here to learn more about the appointment.

Matthew Lamont, managing director at DownUnder GeoSolutions

Matthew Lamont is managing director at DownUnder GeoSolutions which just opened its new, powerful data center west of Houston. Courtesy of DUG

Matthew Lamont isn't technically a Houstonian, but the managing director of Perth, Australia-based DownUnder GeoSolutions gets the honorary title for bringing one of the world's most powerful supercomputers, nicknamed Bubba, to the Houston area. In fact, perhaps Lamont accepts the recognition on behalf of Bubba, who — while inanimate — is definitely a Houstonian.

DUG is heavily investing in Houston, and Bubba is just the start. The company plans to start on a friend for Bubba later this year and bring an even more powerful supercomputer to the market by 2021. Read more about Lamont, Bubba, and all that DUG is doing in Houston here.

Taseer Badar, founder and CEO of ZT Corporate

Taseer Badar is in the business of making money. Courtesy of ZT Corporate

Taseer Badar will shoot it to you straight: Houston startups struggling to find capital might need to look nationally or globally.

"Investors in Houston want positive earnings before interest, tax, and amortization," he says. "But that doesn't mean it's not possible in New York, Dallas, Austin, or other cities. There are technology conferences everywhere, that's a great way to get known as a startup."

As CEO and founder of ZT Corporate with 1,000 investors to manage, he knows private equity, and what it takes to invest. Read more about Badar here.

Taseer Badar is in the business of making money. Courtesy of ZT Corporate

Private equity executive talks diversifying and Houston's investment ecosystem

Featured innovator

It's Taseer Badar's job to keep 1,000 investors happy. As CEO and founder of ZT Corporate, that's just a day in the life for him.

Badar has been in the business for over 20 years, and before that, he was on Wall Street as a financial adviser for Morgan Stanley. He realized the dollar went further in his hometown of Houston, so he came back. He started advising on business plans for people he knew, and earned a lot of loyalty from these early entrepreneurs, and grew ZT from there. He found his way into health care, which made up a good majority of his holdings, until about four years ago when he diversified his company and got into the automotive industry.

Last year, the company celebrated its largest exit — Altus Infusion — and acquisition — six Neighbors ER clinics. He created a nonprofit foundation —The Altus Foundation — and raised over $1 million for assistance for underserved families. Over the past 20 years, Badar grew his company from $28 million in revenue to over $600 million — with no end in sight.

Badar spoke with InnovationMap about his career, the health care industry, and what its like to be in private equity in Houston.

InnovationMap: You've recently diversified to include a startup in your portfolio. Tell me about that company.

Taseer Badar: We have group called Accountable Care as an entity, which we are sustaining analytics. It's the opposite of a fee for service business. It used to be that if a patient got sick, we treat you. Now, it's preventive care. We have a pilot of around 40,000 patients right now. It has a lot of potential and it keeps people healthier. How it works is insurance companies pay you to keep their consumer healthy. Let's say an insurance company pays us $100, and we treat them for $85 and keep the rest for our investors.

IM: How does Houston’s investment ecosystem compare to other cities you work in?

TB: For me, it was really hard to move into that. I am very traditional. We're not a risk-based company; we're very risk averse. For me, this fit into our business. It fell in my lap. I do think generally it's a conservative ecosystem, in my opinion. We're not San Francisco — we're not built like that. Not saying no one does it. I was in New York, and those are the guys who understand [venture capital]. In Houston, we understand oil and gas, and we understand medical and real estate. I think we're way off for the startup [investment] here.

IM: With that being said, what is your advice for tech startups seeking capital, then?

TB: Investors in Houston want positive earnings before interest, tax, and amortization. But that doesn't mean it's not possible in New York, Dallas, Austin, or other cities. There are technology conferences everywhere, that's a great way to get known as a startup.

IM: How have you seen the health care industry evolve?

TB: Texas is a state that has a lot of doctors that are entrepreneurial. I personally feel as though that a lot of the Obamacare, and the accountable care, a lot of practices have been bought by hospitals, so you don't see a lot of freestanding medical practices as much as I used to. At the same time, a lot of the younger doctors aren't as business oriented and want more work-life balance. Because there's less of them, there are opportunities for companies like mine to take care of them. When I started, Altus was one of 50 companies of its kind. Now, we are one of two or three standing in Houston with that type of model.

IM: What are the challenges of managing investors?

TB: We have a lot of retail investors. They are great, and it's much more relation based. But, at the same time, a very high-touch business. That requires a lot of time and effort in a relationship. It's a lot more managing of the process.

IM: What do you look for in an investor?

TB: We look for investors that are accredited investors, and we want someone who understands there's a time horizon, who are looking for an income and an exit play between three and seven years. Someone who understands risk and that it's not buying a stock that can be liquidated.

------

Portions of this interview have been edited.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

European spacecraft developer expands to Houston with U.S. business, new lab

houston hq

European aerospace manufacturer The Exploration Company has established its first U.S. entity and named Space City as its headquarters.

The company announced earlier this month that it has launched TEC Federal to support U.S. government customers and agencies, and to scale The Exploration Company's engineering operations in the country.

Mark Kirasich serves as president of TEC Federal. Kirasich most recently served as the senior director of human spaceflight at Blue Origin after a nearly 40-year career at NASA.

The Exploration Company is developing the reusable Nyx space vehicle. Nyx is designed to take off from any heavy launcher in the world. It will then dock at space stations, retrieve up to 3,000 kilograms of cargo, splash down and return the cargo to Earth. The company aims to make Nyx fully reusable for up to 10 missions, making it a more affordable and sustainable option for aerospace missions.

The Exploration Company completed a successful drop test of the spacecraft in May in the Mojave Desert. The company says Nyx is slated to perform its first flight demonstration in 2028.

In addition to launching the Houston business, The Exploration Company also opened its new Rapid Innovation Lab near Houston's NASA Johnson Space Center on Space Park Drive.

The Exploration Company opened its Rapid Innovation Lab earlier this month. Photo via LinkedIn

The Rapid Innovation Lab features a full-scale mockup of the future Nyx crew capsule as well as ongoing development and testing of the Nyx cargo capsule, according to the company.

The Exploration Company says the new lab will allow its engineers, designers, and operators to prototype and test crew interfaces. It will also support partnerships with NASA personnel and astronauts.

“Houston gives us direct access to the people and expertise that have built and operated human spaceflight systems for decades. We’re excited to invest and expand around that— engineers, operators, and astronauts working together and moving quickly towards building a crew capsule.” Hélène Huby, founder and CEO of The Exploration Company, said in a blog post.

According to The Houston Chronicle, The Exploration Company has about 30 employees in the Houston area.

The company was founded in 2021 by Huby, a French rocket scientist, and has raised more than $350 million in venture capital. It operates out of Germany, France, Luxembourg, Spain and Italy, with offices in the U.S. and the United Arab Emirates. It is also developing a reusable, high-thrust rocket engine known as Storm.

UH lands $4M NIH grant to study early signs of autoimmune disease

NIH funding

The University of Houston recently received a $4 million National Institutes of Health grant to support a 10-year longitudinal study to identify the earliest biological markers of autoimmune disease.

Led by Chandra Mohan, the Hugh Roy and Lillie Cranz Cullen Endowed Professor of Biomedical Engineering, the study aims to examine what causes Systemic Autoimmune Rheumatic Diseases (SARDs) and to identify targets for future treatments. The study will be carried out in collaboration with Dr. Karen Costenbader at Harvard Medical School, Boston.

SARDs include conditions like rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome and systemic sclerosis—all are considered chronic diseases currently without a cure. Autoimmune diseases affect over 30 million people globally, according to UH.

SARDs occur when the body’s immune system attacks healthy, non-threatening tissues and organs. According to UH, in these diseases, the body often attacks nuclear antigens, creating anti-nuclear autoantibodies, which can be early detection signs for SARDs in more than 50 percent of patients, Mohan says.

Researchers will study blood samples and environmental exposure over the 10 years to better understand anti-nuclear autoantibodies.

“Collectively, these studies will help identify the genetic, environmental and cellular factors that are operative at the two steps of SARD development, namely the emergence of anti-nuclear autoantibodies and disease onset,” Mohan said in a news release. “ More importantly, these studies will highlight functional molecular pathways and mechanisms that may be operative at each step."

Mohan predicts that looking at SARDs’ shared characteristics, rather than each disease individually, could help identify more treatment methods.

“Individual SARDs have been examined in silos without an attempt to discern shared underlying features at the molecular level,” he added in the release. “Current understanding of the initial (and likely shared) origins of SARDs is only rudimentary but urgently needed to develop means for prevention and treatment.”

Earlier this year, UH also received an $11 million NIH grant to conduct a first-of-its-kind study of early language development in children ages 18 to 24 months. Read more here.